Dermata Advances with XYNGARI™ Trial Completion for Acne Care
Dermata Therapeutics Completes Final Patient Visit for XYNGARI™ Trial
- Topline results are anticipated soon.
- Each year, millions seek solutions for acne.
- The XYNGARI™ Phase 3 trial included 520 participants.
Dermata Therapeutics, Inc. (NASDAQ: DRMA) proudly announces a significant milestone in its clinical journey. The latest update indicates that the last patient has concluded their final visit in the pivotal Phase 3 clinical trial, known as STAR-1, focusing on XYNGARI™, an innovative topical treatment targeting moderate-to-severe acne. With this completion, the company remains well-positioned to share topline results soon.
Dr. Christopher Nardo, the Chief Development Officer at Dermata, expressed gratitude towards both patients and investigators for their invaluable contributions which ensured adherence to the trial schedule. "Their dedication has been instrumental in bringing this pivotal study to completion. We are committed to sharing topline data soon, which we hope will reflect the potential of XYNGARI™ in transforming acne treatment," he stated.
Meanwhile, Gerry Proehl, Dermata’s Chairman and CEO, shared his enthusiasm regarding the Phase 3 trial's progress. He highlighted the extraordinary need for effective acne products, believing that XYNGARI™ could fulfill this necessity. "XYNGARI™ is uniquely crafted as a once-weekly topical treatment that employs various mechanisms to address the root causes of acne. This innovative approach could mean enhanced efficacy and convenience compared to traditional methods," he noted.
Overview of the XYNGARI™ Phase 3 STAR-1 Clinical Trial
The STAR-1 clinical trial investigates the efficacy, safety, and tolerability of XYNGARI™ among patients facing moderate-to-severe acne. This well-structured trial involved a randomized, double-blind, placebo-controlled design with 520 patients aged 9 and older. Critical endpoints of the study include the evaluation of inflammatory and noninflammatory lesion counts and the Investigator Global Assessment (IGA) treatment response measured on a defined scale. The innovative treatment involved a once-a-week application over a span of 12 weeks for both the treatment and placebo groups.
The completion of patient visits marks the first of two pivotal Phase 3 trials, with positive results potentially leading to filing for a new drug application with the U.S. Food and Drug Administration.
Defining XYNGARI™ and Its Mechanisms
Originally known as DMT310, XYNGARI™ is a groundbreaking topical product derived from freshwater sponge. This unique formulation incorporates both mechanical and chemical properties designed to alleviate inflammatory skin conditions, including acne. The treatment encourages skin exfoliation and enhances collagen production, providing a comprehensive approach to acne management.
In preliminary trials, XYNGARI™ demonstrated a remarkable potential for improvement in acne severity. A large proportion of participants achieved significant reductions in acne symptoms when compared to placebo.
The Acne Epidemic
Acne remains a pervasive issue, affecting millions in the U.S. each year. With around 85% of teenagers experiencing acne and many adults facing persistent breakouts, the condition poses not only aesthetic challenges but also emotional burdens and social implications. Acne can lead to low self-esteem and scar formation, necessitating effective treatment options.
Dermata Therapeutics: Leading the Charge
Dermata Therapeutics stands as a pioneering force in the biotechnology field, concentrating on addressing skin-related medical and aesthetic challenges. XYNGARI™ is at the forefront of their product lineup, with ongoing studies also targeting other skin conditions like psoriasis and rosacea. Additionally, Dermata is innovating further with their needle-free delivery of treatments.
The company's operations are headquartered in San Diego, California. For more detailed information, interested individuals can visit Dermata's official website.
Frequently Asked Questions
What is the primary goal of the STAR-1 clinical trial?
The STAR-1 clinical trial aims to evaluate the efficacy, safety, and tolerability of XYNGARI™ for patients with moderate-to-severe acne.
How many patients were involved in the trial?
A total of 520 patients participated in the Phase 3 STAR-1 clinical trial.
What is unique about XYNGARI™?
XYNGARI™ is designed as a once-weekly topical treatment that employs multiple mechanisms to effectively address acne.
What results are the company expecting?
Dermata anticipates publishing topline results that will potentially highlight XYNGARI™'s effectiveness in treating acne.
Where is Dermata Therapeutics located?
Dermata Therapeutics is headquartered in San Diego, California.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.